Latest CMSC 2016 Coverage
Several participants who began the intervention from a chair were completing the exercise standing up by the end.
Notably, results were achieved without maintenance therapy.
There was a significant association between the average GCIP thickness and MSFC scores.
The new drug shows promise in the treatment of PPMS, for which there are currently no approved treatments.
The material of the device may play a significant role in the relationship.
Patients taking oral DMDs were more likely to experience relapse in the first year.
A comprehensive approach to managing depression may have far-reaching effects.
At follow-up, 22 patients were cognitively impaired compared to 34 at baseline.
Early screening is paramount to identifying patients at risk for suicide.
Neurology Advisor reviews the upcoming agenda for the CMSC annual meeting.
Sign Up for Free e-newsletters
Check out what's trending
Neurology Advisor Articles
- OCD in Duchenne Muscular Dystrophy Features Distinct Phenotype, Associated Symptoms
- History of Migraine Associated With Higher Risk for Cochlear Disorders
- Patent Foramen Ovale Closure for Stroke Prevention: Key Principles for Clinical Practice
- Vagus Nerve Stimulation in Pediatric Epilepsy: Weighing the Risks and Benefits
- A Model for Predicting Quality of Life Improvements After Deep Brain Stimulation
- Some Statins May Be Associated With Cognition, Memory Deficits
- Neuropathic Pain Treatments
- Cannabis for Multiple Sclerosis: Prescriber's Perspective
- New Monoclonal Antibody BAN2401 Reduces Amyloid Plaques, Improves Cognition in Alzheimer's
- Nonpharmacologic Interventions for Alzheimer's Have Greater Impact on Outcomes Than Currently Available Medications
- First-in-Class Therapy Approved for Polyneuropathy Caused by hATTR
- High Anxiety Symptoms Prevalent in Epilepsy, Mesial Temporal Sclerosis
- Advance Care Planning Doesn't Aid Quality of Life
- Variation in Specialty Drug Coverage Across Health Plans
- Alcohol Exposure Via Breastmilk May Affect Infant Development